DUX4 and facioscapulohumeral muscular dystrophy: In response to developing a more targeted form of treatment, reducing muscle-specific DUX4 expression and DUX4-mediated toxicity have become attractive goals for FSHD therapy (Bao et al., 2016; Bouwman et al., 2020; Cohen et al., 2020).